Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of 101-PGC-005 in Healthy Adults
NCT05619770Phase 1Unknown
- Sponsor
- 101 Therapeutics
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 101-PGC-005 in coronavirus disease 2019 (COVID-19), sponsored by 101 Therapeutics. Primary endpoints: Single dose pharmacokinetics at 24 hours and Multiple dose pharmacokinetics at 24 hours. Status: unknown.
02
Drugs
101-PGC-005
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05619770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619770.